Back to Search Start Over

Nephrotoxicity of marketed antisense oligonucleotide drugs.

Nephrotoxicity of marketed antisense oligonucleotide drugs.

Authors :
Wu H
Wahane A
Alhamadani F
Zhang K
Parikh R
Lee S
McCabe EM
Rasmussen TP
Bahal R
Zhong XB
Manautou JE
Source :
Current opinion in toxicology [Curr Opin Toxicol] 2022 Dec; Vol. 32. Date of Electronic Publication: 2022 Oct 21.
Publication Year :
2022

Abstract

The field of antisense oligonucleotide (ASO)-based therapies have been making strides in precision medicine due to their potent therapeutic application. Early successes in treating some genetic diseases are now attributed to an emerging class of antisense drugs. After two decades, the US Food and Drug Administration (FDA) has approved a considerable number of ASO drugs, primarily to treat rare diseases with optimal therapeutic outcomes. However, safety is one of the biggest challenges to the therapeutic utility of ASO drugs. Due to patients' and health care practitioners' urgent demands for medicines for untreatable conditions, many ASO drugs have been approved. However, a complete understanding of the mechanisms of adverse drug reactions (ADRs) and toxicities of ASOs still need to be resolved. The range of ADRs is unique to a specific drug, while few ADRs are common to a section of drugs as a whole. Nephrotoxicity is an important concern that needs to be addressed considering the clinical translation of any drug candidates ranging from small molecules to ASO-based drugs. This article encompasses what is known about the nephrotoxicity of ASO drugs, the potential mechanisms of action(s), and recommendations for future investigations on the safety of ASO drugs.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Details

Language :
English
ISSN :
2468-2934
Volume :
32
Database :
MEDLINE
Journal :
Current opinion in toxicology
Publication Type :
Academic Journal
Accession number :
37193356
Full Text :
https://doi.org/10.1016/j.cotox.2022.100373